JP2015526455A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526455A5
JP2015526455A5 JP2015527915A JP2015527915A JP2015526455A5 JP 2015526455 A5 JP2015526455 A5 JP 2015526455A5 JP 2015527915 A JP2015527915 A JP 2015527915A JP 2015527915 A JP2015527915 A JP 2015527915A JP 2015526455 A5 JP2015526455 A5 JP 2015526455A5
Authority
JP
Japan
Prior art keywords
alkyl
ring
group
replaced
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527915A
Other languages
English (en)
Japanese (ja)
Other versions
JP6278416B2 (ja
JP2015526455A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067427 external-priority patent/WO2014029832A1/en
Publication of JP2015526455A publication Critical patent/JP2015526455A/ja
Publication of JP2015526455A5 publication Critical patent/JP2015526455A5/ja
Application granted granted Critical
Publication of JP6278416B2 publication Critical patent/JP6278416B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527915A 2012-08-23 2013-08-22 置換4−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 Active JP6278416B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12181541 2012-08-23
EP12181541.9 2012-08-23
PCT/EP2013/067427 WO2014029832A1 (en) 2012-08-23 2013-08-22 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity

Publications (3)

Publication Number Publication Date
JP2015526455A JP2015526455A (ja) 2015-09-10
JP2015526455A5 true JP2015526455A5 (enExample) 2016-10-13
JP6278416B2 JP6278416B2 (ja) 2018-02-14

Family

ID=46963419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527915A Active JP6278416B2 (ja) 2012-08-23 2013-08-22 置換4−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用

Country Status (4)

Country Link
US (2) US20140057920A1 (enExample)
EP (1) EP2888249B1 (enExample)
JP (1) JP6278416B2 (enExample)
WO (1) WO2014029832A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US20220354833A1 (en) 2019-09-17 2022-11-10 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
ES2962498T3 (es) 2020-04-16 2024-03-19 Mereo Biopharma 4 Ltd Métodos que implican el inhibidor de elastasa de neutrófilos alvelestat para el tratamiento de enfermedades respiratorias mediadas por deficiencia de alfa-1 antitripsina
US11804467B2 (en) * 2020-06-25 2023-10-31 Micron Technology, Inc. Radiative heat collective bonder and gangbonder
CN112920124B (zh) * 2021-01-29 2024-03-01 安徽医科大学 一种嘧啶-2,4-二胺类化合物及其制备方法与应用
US20240382472A1 (en) 2021-10-20 2024-11-21 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844732A (en) * 1985-10-24 1989-07-04 Daicel Chemical Industries Ltd. Pyridine-3-carboxamide derivatives
WO2001068652A1 (en) 2000-03-17 2001-09-20 Novo Nordisk A/S Condensed imidazoles as histamine h3 receptor ligands
US7211595B2 (en) 2000-11-30 2007-05-01 Abbott Laboratories Farnesyltransferase inhibitors
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds
TW200700392A (en) * 2005-03-16 2007-01-01 Astrazeneca Ab Novel compounds
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2217591A4 (en) 2007-11-06 2011-10-26 Astrazeneca Ab CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS
PT2235002E (pt) * 2008-01-23 2013-01-30 Bristol Myers Squibb Co Compostos de 4-piridinona e a sua utilização para o tratamento do cancro
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
EP2261211A1 (en) 2009-05-20 2010-12-15 Université de Lille 2 Droit et Santé 1,4-dihydropyridine derivatives and their uses
CA2773618A1 (en) 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide

Similar Documents

Publication Publication Date Title
JP2015526455A5 (enExample)
JP2015526453A5 (enExample)
JP2016516020A5 (enExample)
EA201650029A1 (ru) Пиразолопиридины и пиразолопиримидины
JP2014507446A5 (enExample)
JP2015078230A5 (enExample)
JP2014511891A5 (enExample)
JP2015526454A5 (enExample)
JP2016520618A5 (enExample)
JP2015504081A5 (enExample)
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2016501250A5 (enExample)
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
JP2013543896A5 (enExample)
JP2016511262A5 (enExample)
EP2552203A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF VIRUS INFECTIONS
JP2017504611A5 (enExample)
JP2013542261A5 (enExample)
ME03016B (me) Derivat piridina
JP2017506666A5 (enExample)
JP2019531279A5 (enExample)
JP2016507581A5 (enExample)
JP2017509611A5 (enExample)
JP2016515110A5 (enExample)
HRP20151338T1 (hr) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita